SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Qualified Opinion who wrote (3220)9/25/2002 4:22:29 PM
From: biostruggle  Read Replies (2) of 10345
 
Get ready for another large impairment cost this q. Most of Elans investments are way down from June 30. Example Ligand 14+ to 6.56 today times 14 million shares. Approx >100 million on ligand investment alone. RZM, ISIS, INCR, AMRN, DOVP etc are also down considerable.

These impairment charges are no small matter as they reduce Elans equity. There are convenants on QSPE debt in which Elan has to maintain a certain equity, otherwise Elan will be forced to ante up to QSPE note holders.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News